Agomab's Lung Drug Shows >50% Target Reduction in Phase 1, Paving Way for Phase 2
AGMB sits 40% above its 52-week low of $8.75.
Summary
Agomab reported positive Phase 1 data for AGMB-447 in idiopathic pulmonary fibrosis (IPF), showing a >50% reduction in pSMAD3 proteins in lung fluid cells at the 4.5mg twice-daily dose. The drug was generally well tolerated, though the 6mg dose had more adverse events without new safety signals. This supports initiation of the Phase 2 INSPIRIA study later this year. The data validate the mechanism of blocking TGF-beta/ALK5 locally in the lung, a key differentiator for IPF treatment. With a market cap around $643M and cash runway into 2029, this clinical milestone de-risks the program and could attract partnership interest. Watch for Phase 2 initiation and any regulatory feedback on the INSPIRIA design.
At the time of this announcement, AGMB was trading at $12.28 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $643.2M. The 52-week trading range was $8.75 to $17.82. This news item was assessed with positive market sentiment and an importance score of 8 out of 10. Source: Dow Jones Newswires.